Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach.

Decision making Lung cancer Multidisciplinary Non-small cell lung cancer Treatment guidelines

Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
02 2021
Historique:
received: 17 06 2020
accepted: 20 10 2020
pubmed: 5 11 2020
medline: 22 6 2021
entrez: 4 11 2020
Statut: ppublish

Résumé

Non-small cell lung cancer (NSCLC) accounts for approximately one in five cancer-related deaths, and management requires increasingly complex decision making by health care professionals. Many centers have therefore adopted a multidisciplinary approach to patient care, using the expertise of various specialists to provide the best evidence-based, personalized treatment. However, increasingly complex disease staging, as well as expanded biomarker testing and multimodality management algorithms with novel therapeutics, have driven the need for multifaceted, collaborative decision making to optimally guide the overall treatment process. To keep up with the rapidly evolving treatment landscape, national-level guidelines have been introduced to standardize patient pathways and ensure prompt diagnosis and treatment. Such strategies depend on efficient and effective communication between relevant multidisciplinary team members and have both improved adherence to treatment guidelines and extended patient survival. This article highlights the value of a multidisciplinary approach to diagnosis and staging, treatment decision making, and adverse event management in NSCLC. IMPLICATIONS FOR PRACTICE: This review highlights the value of a multidisciplinary approach to the diagnosis and staging of non-small cell lung cancer (NSCLC) and makes practical suggestions as to how multidisciplinary teams (MDTs) can be best deployed at individual stages of the disease to improve patient outcomes and effectively manage common adverse events. The authors discuss how a collaborative approach, appropriately leveraging the diverse expertise of NSCLC MDT members (including specialist radiation and medical oncologists, chest physicians, pathologists, pulmonologists, surgeons, and nursing staff) can continue to ensure optimal per-patient decision making as treatment options become ever more specialized in the era of biomarker-driven therapeutic strategies.

Identifiants

pubmed: 33145902
doi: 10.1002/onco.13586
pmc: PMC7873339
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e306-e315

Subventions

Organisme : Medical Research Council
ID : MR/T02481X/1
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.

Références

JAMA Oncol. 2019 Jul 01;5(7):1008-1019
pubmed: 31021376
J Thorac Oncol. 2018 Dec;13(12):1842-1850
pubmed: 30312680
J Thorac Dis. 2015 Jul;7(7):1098-102
pubmed: 26380721
Ann Oncol. 2020 Jun;31(6):798-806
pubmed: 32209338
Memo. 2018;11(2):132-137
pubmed: 29983828
Clin Lung Cancer. 2018 Sep;19(5):e783-e799
pubmed: 29983370
Ann Oncol. 2020 Feb;31(2):191-201
pubmed: 31959336
BMJ Open. 2015 Dec 18;5(12):e008587
pubmed: 26685023
J Thorac Oncol. 2017 Sep;12(9):1398-1402
pubmed: 28583587
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Thorax. 2018 Jun;73(6):530-537
pubmed: 29511056
J Natl Cancer Inst. 2013 Jan 16;105(2):113-21
pubmed: 23274388
Cancer Epidemiol. 2015 Aug;39(4):612-6
pubmed: 25979251
J Thorac Oncol. 2018 Nov;13(11):1762-1770
pubmed: 30138763
JCO Precis Oncol. 2017 May 26;1:
pubmed: 32913972
J Clin Pathol. 2014 Nov;67(11):923-31
pubmed: 25012948
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Thorax. 2010 Oct;65 Suppl 3:iii1-27
pubmed: 20940263
Histopathology. 2016 Aug;69(2):177-86
pubmed: 27196116
JAMA Oncol. 2017 Apr 01;3(4):524-548
pubmed: 27918777
J Thorac Dis. 2018 Sep;10(Suppl 26):S3203-S3206
pubmed: 30370113
Thorax. 2011 Dec;66(12):1078-84
pubmed: 21785158
Clin Oncol (R Coll Radiol). 2019 Oct;31(10):681-687
pubmed: 31377081
Ann Oncol. 2012 Oct;23(10):2743-2747
pubmed: 22553198
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Eur Respir J. 2010 Apr;35(4):717-20
pubmed: 20356981
JCO Clin Cancer Inform. 2018 Dec;2:1-12
pubmed: 30652540
Sci Rep. 2019 Feb 14;9(1):2094
pubmed: 30765832
J Thorac Dis. 2018 Feb;10(Suppl 3):S404-S411
pubmed: 29593886
World J Clin Oncol. 2017 Feb 10;8(1):1-20
pubmed: 28246582
J Thorac Oncol. 2020 Feb;15(2):288-293
pubmed: 31622733
Br J Cancer. 2013 Oct 29;109(9):2295-300
pubmed: 24084764
Lancet Respir Med. 2015 Apr;3(4):282-9
pubmed: 25660225
Curr Oncol. 2012 Jun;19(Suppl 1):S7-S15
pubmed: 22787414
J Thorac Oncol. 2013 Jan;8(1):68-72
pubmed: 23242439
J Thorac Dis. 2015 Sep;7(9):E311-25
pubmed: 26543620
J Clin Oncol. 2018 Mar 1;36(7):710-719
pubmed: 29106810
ERJ Open Res. 2019 Jul 15;5(3):
pubmed: 31321223
Radiol Oncol. 2018 Sep 6;53(1):1-5
pubmed: 30840590
Ann Oncol. 2019 Feb 1;30(2):171-210
pubmed: 30596843
J Thorac Dis. 2018 Feb;10(Suppl 3):S451-S459
pubmed: 29593890
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Respirology. 2015 Aug;20(6):884-8
pubmed: 25847500
J Thorac Oncol. 2018 Jun;13(6):767-778
pubmed: 29654928
Lung Cancer. 2020 Dec;150:221-239
pubmed: 33227525
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
Eur Respir J. 2017 Jan 3;49(1):
pubmed: 28049169
J Thorac Oncol. 2018 Sep;13(9):1302-1311
pubmed: 29800747
Chest. 2013 May;143(5 Suppl):e278S-e313S
pubmed: 23649443
J Psychosom Res. 2008 Dec;65(6):549-52
pubmed: 19027443
Thorax. 2016 Feb;71(2):177-84
pubmed: 26530085
Lung Cancer. 2016 Jan;91:48-55
pubmed: 26711934
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236
J Thorac Oncol. 2007 Dec;2(12):1091-7
pubmed: 18090580
Ann Oncol. 2015 Aug;26(8):1573-88
pubmed: 25897013
J Thorac Oncol. 2020 Mar;15(3):344-359
pubmed: 31731014
PLoS One. 2015 May 12;10(5):e0126547
pubmed: 25966317
Crit Rev Oncol Hematol. 2015 Nov;96(2):319-27
pubmed: 26095618
BMJ. 2019 Mar 28;364:l1049
pubmed: 30923038
Lung Cancer. 2005 Jul;49(1):25-33
pubmed: 15949587
Clin Lung Cancer. 2017 Nov;18(6):651-659
pubmed: 28479369
Thorax. 2018 Mar;73(3):290-292
pubmed: 29056599
Patient Educ Couns. 2016 Nov;99(11):1808-1813
pubmed: 27372523
Int J Gen Med. 2017 Sep 18;10:305-310
pubmed: 29075134
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
Ann Thorac Surg. 2018 Nov;106(5):1492-1498
pubmed: 29908981
J Thorac Oncol. 2019 Dec;14(12):2109-2119
pubmed: 31398540

Auteurs

Sanjay Popat (S)

Lung Unit, Royal Marsden Hospital, London, United Kingdom.
The Institute of Cancer Research, University of London, London, United Kingdom.

Neal Navani (N)

Lungs for Living Research Centre, University College London (UCL) Respiratory, UCL and Department of Thoracic Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

Keith M Kerr (KM)

Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, United Kingdom.

Egbert F Smit (EF)

Department of Pulmonary Diseases, VU University Medical Center and Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Timothy J P Batchelor (TJP)

Department of Thoracic Surgery, University Hospitals Bristol and Weston National Health Service Foundation Trust, Bristol, United Kingdom.

Paul Van Schil (P)

Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium.

Suresh Senan (S)

Department of Radiation Oncology, Amsterdam University Medical Center, Free University Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Fiona McDonald (F)

Lung Unit, Royal Marsden Hospital, London, United Kingdom.
The Institute of Cancer Research, University of London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH